ABVC BIOPHARMA, INC. Stock Compensation Disclosure
13. STOCK OPTIONS
The Company has not granted any options during years ended December 31, 2024 and 2023. The Company’s most recent option grant was in 2022 that 76,190 shares (post-split) of common stock were granted to employees and certain consultants. The weighted average grant date fair value of options granted in 2022 was $27.9 (post-split). There are 386,021 options available for grant under the 2016 Equity Incentive Plan as of December 31, 2024. Compensation costs associated with the Company’s stock options are recognized, based on the grant-date fair values of these options over vesting period. As of December 31, 2024 and 2023, there were no unvested options.
Options issued and outstanding as of December 31, 2024, and their activities during the year then ended are as follows:
| Weighted- | Weighted- | |||||||||||||||
| Average | Average | |||||||||||||||
| Number of | Exercise | Contractual | ||||||||||||||
| Underlying Shares (post-split) | Price Per Share (post-split) | Life Remaining in Years | Aggregate Intrinsic Value | |||||||||||||
| Outstanding as of January 1, 2024 | 258,710 | $ | 27.9 | 7.74 | ||||||||||||
| Granted | ||||||||||||||||
| Forfeited | ||||||||||||||||
| Outstanding as of December 31, 2024 | 258,710 | 27.9 | 7.74 | $ | ||||||||||||
| Exercisable as of December 31, 2024 | 258,710 | 27.9 | 7.74 | $ | ||||||||||||
| Vested and expected to vest | 258,710 | $ | 27.9 | 6.74 | $ | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Apr 15, 2025 | Showing above |
| 2023 | Mar 13, 2024 | |
About Stock Compensation Disclosures
Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.
Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.